What is the appropriate management for a 44-year-old patient with major depressive disorder, generalized anxiety disorder, and attention‑deficit/hyperactivity disorder who is experiencing acute anxiety and insomnia related to the upcoming birthday of a relative who died two years ago?

Management of Acute Anxiety and Insomnia in a Patient with MDD, GAD, and ADHD Experiencing Anticipatory Grief

Treat the anxiety disorder first before addressing ADHD, using either cognitive behavioral therapy (CBT) or a second-generation antidepressant (SSRI/SNRI) as monotherapy, with short-term benzodiazepine bridging for acute insomnia and severe anxiety symptoms. 1, 2, 3

Prioritize Anxiety Treatment Over ADHD

• The anxiety disorder must be treated until clear symptom reduction is observed before initiating or optimizing ADHD medications. 1
• Treating ADHD first in the presence of significant anxiety symptoms leads to poor outcomes and may worsen anxiety. 1
• This patient's acute anxiety with nocturnal checking behaviors (likely related to anticipatory grief around the deceased relative's birthday) represents a psychiatric emergency requiring immediate intervention. 2

First-Line Treatment Options

Pharmacotherapy Approach

• Initiate a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) as first-line treatment for the comorbid MDD and GAD. 4, 3
• SSRIs are considered first-line treatment for depression comorbid with anxiety disorders. 2
• Add a short-acting benzodiazepine as a "bridging strategy" for 2-4 weeks to address the acute anxiety and insomnia while the antidepressant reaches therapeutic effect. 2, 5
• Benzodiazepines beyond 4 weeks cause rebound anxiety and withdrawal symptoms, so limit duration strictly. 5

Psychotherapy Approach

• CBT monotherapy is an alternative first-line option, particularly for patients who prefer to avoid medications or have concerns about antidepressant side effects. 4, 3
• CBT is efficacious for both GAD and depression and addresses the intolerance of uncertainty and avoidance behaviors evident in this patient's nocturnal checking. 2

Combination Therapy

• Consider combining CBT with an SSRI/SNRI from the outset, as combination therapy may be superior to monotherapy in comorbid anxiety and depression. 3
• The combination approach is particularly appropriate when anxiety symptoms are severe and causing significant functional impairment (as evidenced by sleep disruption). 2

Critical Caveats About SSRI/SNRI Initiation

• SSRIs and SNRIs can transiently increase anxiety symptoms during the first 1-2 weeks, manifesting as jitteriness, agitation, insomnia, and gastrointestinal symptoms. 6
• This is why benzodiazepine bridging is essential in this acutely anxious patient. 2
• If the patient cannot tolerate benzodiazepines (e.g., history of substance abuse), use an atypical antipsychotic such as quetiapine for acute anxiety instead. 2

ADHD Management Considerations

• Do not initiate or increase stimulant medications for ADHD until anxiety symptoms are substantially reduced. 1
• Stimulants can exacerbate anxiety and insomnia in patients with active GAD. 4, 1
• If ADHD treatment is already established, consider temporarily reducing the dose or switching to a non-stimulant option (atomoxetine or guanfacine) during this acute anxiety crisis. 4

Addressing the Grief Component

• The patient's symptoms represent complicated grief with anniversary reactions, requiring specific attention to the upcoming birthday trigger. 2
• CBT should incorporate grief-focused interventions and preparation for the anniversary date. 2
• Anticipate that symptoms may temporarily worsen around the actual birthday date and plan increased support during that period. 2

Treatment Sequencing Algorithm

1. Week 1-2: Start SSRI/SNRI + short-acting benzodiazepine + initiate CBT if available. 2, 3
2. Week 2-4: Continue SSRI/SNRI, taper benzodiazepine as antidepressant effect emerges. 2, 5
3. Week 4-8: Assess anxiety and depression response; if inadequate, increase antidepressant dose or augment with CBT if not already implemented. 3
4. Week 8-12: Once anxiety symptoms show clear reduction, consider optimizing ADHD treatment if still needed. 1

If Initial Treatment Fails

• For inadequate response after 6-8 weeks, switch to a different SSRI/SNRI or augment with an atypical antipsychotic (aripiprazole, quetiapine, or risperidone). 2, 3
• Augmentation with CBT is preferred over medication switching if the patient has shown partial response. 3
• Combination therapy with tricyclic antidepressants or duloxetine may be considered if comorbid chronic pain is present. 2

High-Risk Considerations

• Patients with comorbid anxiety and depression have greater suicide risk, particularly with somatic anxiety symptoms like this patient's sleep disruption. 6
• Assess suicide risk at every visit, especially around the anniversary date. 7, 6
• The patient's nocturnal checking behavior suggests significant functional impairment requiring aggressive treatment. 7